The QualityStocks Daily Thursday, July 28th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(ATHX) $0.3250 +71.05%

Early Bird(JAKK) $22.4600 +31.50%

Schaeffer's(RUN) $30.9200 +29.97%

The QualityStocks Daily Stock List

Athersys (ATHX)

Streetwise Reports, MarketBeat, Wall Street Resources, BUYINS.NET,, QualityStocks, MarketClub Analysis, TraderPower, The Street, StreetInsider, News, StockMarketWatch, PennyStocks24, TradersPro, Seeking Alpha, Street Insider, InvestorPlace, SmarTrend Newsletters, Greenbackers, PennyOmega, FeedBlitz, InvestorsUnderground, Wealth Insider Alert, CRWEWallStreet, CRWEPicks, CRWEFinance, WealthMakers, BioTech Play, BestOtc, DrStockPick, Trades Of The Day, PennyToBuck, Momentum Traders, StockTradersHQ, PCG Advisory, Barchart, The Momentum Traders Network, Zacks, Short Term Wealth, SmallCapReview, SmallCapVoice, Stock Beast, StockHotTips and MicrocapVoice reported earlier on Athersys (ATHX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Athersys Inc. (NASDAQ: ATHX) (FRA: 4LS) is a biotechnology firm that is involved in the research, discovery and development of allogeneic stem cell products that have been designed to treat cardiovascular disease, pulmonary and neurological conditions, immune disorders and inflammatory disorders, in addition to other conditions.

Athersys Inc. is based in Cleveland, Ohio and was established on October 24, 1995 by Gil van Bokkelen and John J. Harrington. The company serves consumers across the globe.

Athersys Inc. is party to collaboration and license agreements with the University of Minnesota for the development of a MultiStem cell therapy platform and with Healios K.K. for the development and commercialization of MultiStem cell therapy for ophthalmological indications, acute respiratory distress syndrome, ischemic stroke and also the treatment of intestinal tissue, pancreas, kidney and liver diseases.

Athersys Inc., which operates in the field of regenerative medicine, has developed the following product: MultiStem cell therapy. The stem cell therapy recently concluded a phase 1 clinical study for the treatment of leukemia and other blood borne cancers and is currently undergoing its phase 2 clinical study for the treatment of acute myocardial infarction and a phase 3 clinical study for the treatment of neurological damaged brought about by an ischemic stroke. The therapy is also used to facilitate healing and tissue repair for animal patients, including those who suffer from severe conditions with unmet medical needs.

Athersys Inc.’s and Healios K.K.’s cooperation agreement will help both companies advance their late-stage MultiStem programs. Many anticipate that the product may soon be approved in Japan, which would not only change the lives of many patients but also help broaden both companies’ international network of alliances and collaborations, which will help boost growth and investments.

Athersys (ATHX), closed Thursday's trading session at $0.325, up 71.0526%, on 267,907,343 volume. The average volume for the last 3 months is 267.907M and the stock's 52-week low/high is $0.1708/$1.81.

SunHydrogen (HYSR)

QualityStocks, Investor News Source, OTCPicks, Stock Preacher, InvestorPlace, Beacon Equity Research, StockHideout, InvestorSoup, PennyTrader Publisher, MicroStockProfit, Penny Stocks Finder, TheLightningPicks, Stock Roach, Wallstreetlivechat, SmallCapStockPlays, Hotstocked, FeedBlitz, Wise Alerts, Investors Online Bell, OTCReporter, Penny Stock Finder,, Top Stock Picks,, TopPennyStockMovers, Crazy Carl,, Greenbackers,,,,,, Stockpalooza, Penny Stock Craze, Real Pennies, Pumps and Dumps,, LightningStockPicks, Nebula Stocks,, AimHighProfits and TheMicrocapNews reported earlier on SunHydrogen (HYSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sunhydrogen Inc. (OTC: HYSR) is focused on generation and marketing of renewable energy and is engaged in the provision of renewable energy services.

The company is based in Santa Barbara, California and incorporated in 2009, on February 18th. It serves consumers in the state of California. Prior to its name change, the firm was known as Hypersolar Inc.

SunHydrogen caters to metal processing, ammonia production, refineries and other sectors and produces economical renewable hydrogen using sunlight. It has developed a nanoparticle system that’s solar-powered and imitates photosynthesis to separate hydrogen from water. It plans to get this system’s technology to be licensed, allowing it to be used in producing renewable hydrogen and electricity for fuel cells. It generates energy from sunlight.

Its technology, the HyperSolar H2Generator, is used to develop a submersible hydrogen production particle which splits H2O molecules under the sun. Every particle is a complete hydrogen generator and contains a high voltage solar cell that’s bonded to chemical catalysts via an encapsulation coating. It is also developing a modular system that will allow for the daily production and storage of hydrogen that can be used at any time in the manufacture of fertilizer, oil and gas refining, the generation of electricity and any other hydrogen applications.

The company recently appointed a new Board Director and Chief Operating Officer, who has under his belt years of experience and is known for his strategic approach and leadership in operations management. This move will aid in the expansion of the firm’s brand footprint and global relationships, which will bring in investments.

SunHydrogen (HYSR), closed Thursday's trading session at $0.0481, up 46.2006%, on 49,000,050 volume. The average volume for the last 3 months is 49M and the stock's 52-week low/high is $0.0211/$0.0919.

Q&K International Group (QK)

StreetInsider and QualityStocks reported earlier on Q&K International Group (QK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Q&K International Group Limited (NASDAQ: QK) is a holding firm that is focused on providing and operating a long-term apartment rental platform as well as providing other real estate services.

The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in 2012 by Guang Jie Jin. It operates in the real estate sector, under the real estate services sub-industry and serves consumers in China.

The enterprise is strategically focused on sourcing apartments under the lease-and-operate model in locations that are relatively inexpensive, to offer their tenants value for money. It applies technology to each step of its operations, from renovation and apartment sourcing to tenant acquisition. This allows the enterprise to operate a fast-growing portfolio of apartments with high operational efficiency, enabling them to deliver superior user experience.

The company provides branded apartments as well as facilitates value-added services. It leases apartments from landlords and then renovates them into standardized furnished rooms, which can then be leased to young individuals who seek affordable, ready-to-move-in, conveniently located residences in cities. In addition, it cooperates with 3rd parties, including e-commerce firms and professional home service providers, to provide value-added services to its tenants. The company also offers utility services and internet connection as part of its lease agreements.

The firm is focused on growing organically and is working on acquiring high quality assets. Its management team is also focused on improving the firm’s ability to execute its growth strategy and strengthening the business, which is bound to bring in more investors.

Q&K International Group (QK), closed Thursday's trading session at $1.87, up 30.7692%, on 141,635 volume. The average volume for the last 3 months is 141,510 and the stock's 52-week low/high is $0.601/$6.70.

Aridis Pharmaceuticals (ARDS)

StreetInsider, RedChip, MarketBeat, BUYINS.NET, StockMarketWatch, Schaeffer's, QualityStocks, Buzz Stocks, HotOTC, OTCtipReporter, Penny Pick Finders, PennyStockProphet, Profitable Trader Authority, TopPennyStockMovers, Red Chip, StockOnion and PennyStockScholar reported earlier on Aridis Pharmaceuticals (ARDS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) is a biopharmaceutical firm that is engaged in the discovery and development of targeted immunotherapies through the use of fully human mAb (monoclonal antibodies) for the treatment of life-threatening fatal infections.

The firm has its headquarters in Los Gatos, California and was incorporated in 2003 by Vu L. Truong and Eric J. Patzer. It operates as part of the pharmaceutical industry, under the healthcare sector and serves consumers in the U.S.

The company’s product portfolio comprises of a trio of clinical stage mAb and three additional pre-clinical anti-infective drug candidates. mAb’s are an innovative treatment approach which has been designed to overcome the deficiencies associated with present therapies, like negative effect on the human microbiome and drug resistance. This approach uses the human immune system to fight infections.

The enterprise’s formulations include an anti-infective therapy dubbed AR-501 which is currently in its phase 1/2a clinical trials to test its effectiveness in managing acute pneumonia in VAP (ventilator-associated pneumonia) and HAP (hospital-acquired pneumonia) patients and chronic lung infections in cystic fibrosis patients; a preclinical program known as AR-201 developed for respiratory syncytial virus; and a formulation dubbed AR-401, developed to treat infections caused by Acinetobacter baumannii. This is in addition to developing a fully human IgG1 mAb dubbed AR-301, which is undergoing phase 3 pivotal trials evaluating its effectiveness in treating lung infections caused by S. aureus alphatoxin.

The company recently entered into an exclusive licensing agreement with AstraZeneca for the suvratoxumab mAb formulation which is indicated for pulmonary infection management. It is now focused on demonstrating the potential for this particular formulation in fulfilling an unmet medical need in a high-risk and very vulnerable population. The company’s success will grow investments into the firm, which will be good for its growth.

Aridis Pharmaceuticals (ARDS), closed Thursday's trading session at $1.92, up 37.1429%, on 1,786,390 volume. The average volume for the last 3 months is 1.786M and the stock's 52-week low/high is $0.88/$5.25.

Solar Integrated Roofing (SIRC)

MoneyTV, Wall Street Mover, TopPennyStockMovers, InvestorPlace, Profitable Trader Authority, PoliticsAndMyPortfolio, OTCtipReporter, SmallCapVoice, Small Cap Firm, QualityStocks, Planet Penny Stocks, PHUB News, PennyStockScholar, DSR News and Buzz Stocks reported earlier on Solar Integrated Roofing (SIRC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solar Integrated Roofing Corp (OTC: SIRC) is an integrated single-source solar power, roofing and HVAC (heating, ventilation and air conditioning) systems installation firm.

The firm has its headquarters in El Cajon, California and was incorporated in 2007, on May 1st by Dave Massey. Prior to its name change in November 2015, the firm was known as Landstar Development Group Inc. The firm serves consumers in the United States.

The company specializes in residential and commercial property development, joint venture partnerships, government land use, land banking, home building and water & sewer utility construction and operations. It serves communities by delivering the best experience through legacy-focused leadership and constant innovation.

The enterprise’s broad array of solutions includes solar energy battery systems, battery backup and electric vehicle charging stations to HVAC, roofing and related electrical contracting work. Its projects include Willowcrest Condos, Tuscan Hills, the Vineyards, LTV Plaza, Hacienda Heights and Desert Willows. The enterprise provides its services to residential and commercial properties and facilities through the following brands: SunUp Solar, Cornerstone Construction, Approved Home Pros, Enerev Solar, USA Solar Networks, PLEMCo, Secure Roofing and Solar, Future Home Power, SunPower by Milholland Electric, Balance, McKay Roofing Co. and Montross Companies.

The firm, which has made a number of high-margin acquisitions, recently reported its latest financials that show significant increases in its revenue. It is focused on generating more shareholder value and the integration of its acquired companies, which will allow it to capture the full revenue lifecycle of its consumers.

Solar Integrated Roofing (SIRC), closed Thursday's trading session at $0.2413, up 31.8579%, on 4,974,878 volume. The average volume for the last 3 months is 4.975M and the stock's 52-week low/high is $0.115/$0.65.

Stryve Foods (SNAX)

QualityStocks, Integrity Solution IR, PennyStocks24, TopPennyStockMovers, StockRich, StockEgg, PennyStockVille, PennyInvest, MarketBeat, MadPennyStocks, HotOTC, CoolPennyStocks, BullRally, AllPennyStocks and Schaeffer's reported earlier on Stryve Foods (SNAX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Stryve Foods Inc. (NASDAQ: SNAX) is a healthy snacking firm that is focused on manufacturing, marketing and selling snacking products.

The firm has its headquarters in Plano, Texas and was incorporated in 2016, on July 29th. Prior to its name change, the firm was known as Andina Acquisition Corp III. It operates as part of the packaged foods industry, under consumer defensive sector. The firm serves consumers in North America, with a primary focus on those in the United States.

The company’s mission is to help individuals snack better and live better, happier lives. It is currently focused on marketing highly differentiated healthy snacks which disrupt the traditional snacking categories.

The enterprise provides snacks that are lower in carbohydrates and sugar and higher in protein, in comparison to other snacks. Its product portfolio comprises primarily of air-dried meat snack products, which are marketed under the following brand names: Vacadillos, Braaitime, Kalahari and Stryve. Its Stryve brand provides biltong products like biltong sticks and sliced biltong, which come in various flavors including spicy peri peri, teriyaki, zesty garlic and cajun. The enterprise also produces meat crisps, chili bites, meat sticks and carne seca products, as well as nutrition products. It distributes its products through retail channels like club stores and groceries, as well as via ecommerce websites.

The company recently reported its latest financial results, which show increases in its net sales. It remains focused on advancing its retail strategy, which will help grow its sales and bring in additional revenues into the company.

Stryve Foods (SNAX), closed Thursday's trading session at $0.7397, up 4.9667%, on 284,793 volume. The average volume for the last 3 months is 284,781 and the stock's 52-week low/high is $0.6084/$8.67.

SpringBig Holdings (SBIG)

MarketBeat reported earlier on SpringBig Holdings (SBIG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SpringBig Holdings Inc. (NASDAQ: SBIG) is a software platform that is engaged in the provision of marketing automation and customer loyalty solutions to cannabis brands and retailers.

The firm has its headquarters in Boca Raton, Florida and was incorporated in 2020, on January 24th. It operates as part of the software-application industry, under the technology sector. The firm serves consumers in Canada and the United States.

The company offers its clients a fully fledged analytics dashboard that provides deep learning insights into the sales of all their marketing channels, which enables them to adjust their marketing tactics and strategies while also boosting the margins on their best performing products by effectively marketing their marijuana dispensaries or brands.

The enterprise’s platform connects consumers with brands and retailers, mainly through SMS marketing, as well as loyalty programs, customer feedback system and emails, to help support brands’ and retailers’ customer engagement and retention. Its reporting and analytics offerings also offer insights that clients can use to understand their customer base, trends and purchasing habits. In addition to this, the enterprise provides marketing automation solutions which offer consistency of customer communication, which in turn helps drive retail foot traffic and customer retention.

The company recently entered into an exclusive partnership with Kind+, which will greatly benefit cannabis businesses by allowing them to reach new audiences as well as new heights. This move, which will help extend the company’s consumer reach, will also open it up to new growth opportunities and help create shareholder value.

SpringBig Holdings (SBIG), closed Thursday's trading session at $1.75, up 4.1667%, on 293,795 volume. The average volume for the last 3 months is 293,795 and the stock's 52-week low/high is $1.56/$5.44.

Quad/Graphics (QUAD)

The Online Investor, StreetInsider,, MarketBeat, InvestorPlace, The Street, BUYINS.NET, StockMarketWatch, Kiplinger Today, MarketClub Analysis, TradersPro, Investing Lab, Darwin Investing Network, Hit and Run Candle Sticks, Investing Futures, Barchart, One Hot Stock, Wealthpire Inc., Stockhouse,, Trades Of The Day, TrendAdvisor and Money Morning reported earlier on Quad/Graphics (QUAD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quad/Graphics, Inc. (NASDAQ: QUAD) (FRA: QGU) is engaged in the provision of media solutions, print solutions, marketing solutions and logistics services.

The firm has its headquarters in Sussex, Wisconsin and was incorporated in 1971, on July 13th by Thomas A. Quadracci and Harry V. Quadracci. It operates as part of the specialty business services industry, under the industrials sector. The firm serves consumers around the globe, with a focus on the United States.

The company operates through the Corporate, International and the United States Print and Related Services. The Corporate segment comprises of unallocated administrative and general activities and associated expenses, including human, information technology, finance, legal and executive resources; while the U.S. Print segment is involved in printing operations. On the other hand, the International segment provides printed services and products like directories, retail inserts books, direct mail, special insert publications, consumer magazines and catalogs, as well as commercial, packaging and printed products.

The enterprise offers marketing and other services, which include campaign planning and creation, consumer insights, process optimization, media planning and placement, personalization, audience targeting, photography, videography, pre-media production, logistics, digital and print execution. The enterprise serves blue chip firms that operate in a range of industries as well as direct marketers, publishers and retailers.

The firm, which recently announced its latest financial results showing increases in its net sales, remains focused on making strategic investments in technology, equipment and talent to accelerate its growth. This will bring in additional revenues and investments into the firm while bolstering its overall growth.

Quad/Graphics (QUAD), closed Thursday's trading session at $3.16, up 2.9316%, on 163,479 volume. The average volume for the last 3 months is 162,396 and the stock's 52-week low/high is $2.55/$7.55.

PolyPid Ltd (PYPD)

MarketBeat and StreetInsider reported earlier on PolyPid Ltd (PYPD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PolyPid Ltd (NASDAQ: PYPD) is a late-stage biopharmaceutical firm that is focused on the development, manufacture and commercialization of products based on its PLEX platform.

The firm has its headquarters in Petah Tikva, Israel and was incorporated in 2007 by Noam Emanuel. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s objective is to address unmet medical needs through the delivery of active pharmaceutical ingredients. It has developed its PLEX (polymer-lipid encapsulation matrix) platform to be paired with medications and enable precise drug delivery at effective rates of release, over a pre-determined duration that may range between a couple of days to some months. The company is subject to extensive regulation by the Food and Drug Administration, under the Federal, Drug and Cosmetic Act as well as by other local, state and federal regulatory agencies.

The enterprise’s product pipeline is comprised of a formulation known as D-PLEX100, which is undergoing phase 3 clinical trials which evaluate its effectiveness in preventing abdominal SSIs (surgical site infections). It is also undergoing trials testing its efficacy in preventing sternal (bone) surgical site infections. The enterprise’s trademarks include S-PLEX, PLEX, BonyPid-500, BonyPid-1000 and BonyPid.

The company recently appointed a new CEO who has a strong background in the sector as well as the ability to guide the company’s operational and strategic objectives. This move will help drive the company’s growth and help create value for its shareholders.

PolyPid Ltd (PYPD), closed Thursday's trading session at $5.19, up 0.776699%, on 7,701 volume. The average volume for the last 3 months is 7,701 and the stock's 52-week low/high is $3.92/$9.64.

Xos Inc. (XOS)

We reported earlier on Xos Inc. (XOS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Xos Inc. (NASDAQ: XOS) (FRA: 9KR) is a mobility solutions firm that is focused on manufacturing and selling battery-electric commercial vehicles.

The firm has its headquarters in Los Angeles, California and was incorporated in 2020, on July 29th by Gregory L. Summe and George N. Mattson. It operates as part of the farm and heavy construction machinery industry, under the industrials sector. The firm serves consumers in the United States.

The company is focused on designing and manufacturing fleet management software, purpose-built commercial zero emission EVs and charging infrastructure to accelerate adoption. Electric fleets are more cost-efficient and can combat expensive fuel and maintenance costs, as well as increasing emissions regulations.

The enterprise has developed a vehicle chassis platform known as the X-Platform and a battery system known as the X-Pack, which have been designed for the medium and heavy-duty commercial vehicle segment. It provides its powertrain technology along with integration and design to other original equipment manufacturers in the off-highway, commercial and industrial markets. This is in addition to offering a range of services to facilitate the transition of traditional combustion engine fleets to battery-electric vehicles. These services include vehicle maintenance, charging infrastructure and financing services.

The firm is party to a partnership agreement with Zeem Solutions, which involves providing its battery-electric vehicles for lease under Zeem’s fleet-as-a-service offering. This move not only helps the firms make strides towards decarbonizing transportation but also opens the firm up to new opportunities and investments, which will be good for its overall growth.

Xos Inc. (XOS), closed Thursday's trading session at $1.84, up 3.3708%, on 272,905 volume. The average volume for the last 3 months is 271,865 and the stock's 52-week low/high is $1.70/$9.00.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, StreetInsider, TopStockAnalysts, Money Morning, Investopedia, Daily Trade Alert, Louis Navellier, VectorVest, Zacks, Trading Markets,, The Growth Stock Wire, ProfitableTrading, Daily Wealth, The Wealth Report, TheStockAdvisors, Top Pros' Top Picks, StreetAlerts, Wall Street Elite, All about trends, Leeb's Market Forecast, TradingMarkets, Streetwise Reports, The Online Investor, Market FN, Market Report, Dividend Opportunities, TheStockAdvisor, InvestmentHouse, StockTwits, Investor Guide, Investors Alley, Trading Concepts, Wealth Insider Alert, Investment House, Money and Markets, Market Intelligence Center Alert, Trading Tips, Options Trader Elite, The Best Newsletters, QualityStocks, InvestorGuide, Energy and Capital, Darwin Investing Network, Buttonwood Research, The Motley Fool, Trade of the Week, AnotherWinningTrade, Wealth Daily, Investing Signal, Wyatt Investment Research, Bourbon and Bayonets, MarketWatch, Market Authority, Investor Update, Profit Confidential, Wall Street Daily, Super Stock Investor, Street Insider, TradingAuthority Daily, Cabot Wealth, Wealthpire Inc., Stock Research Newsletter, InvestorsUnderground, CNBC Breaking News, Daily Markets, AllPennyStocks, Uncommon Wisdom, FeedBlitz, Normandy Investment Research and 24/7 Trader reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Freeport-McMoRan Inc. (NYSE: FCX) recently posted its released profit figures last week, which show lower figures than expected per estimates. This comes as the price for copper drops amid coronavirus lockdowns in China as well as widespread fears of a global recession.

Freeport, which is said to be the largest publicly traded miner of copper globally, reported a net income of $840 million for the second quarter of this year. This is equal to about 57 cents per share and represents a drop from the almost $1 billion recorded in the same period last year.

Refinitiv data also shows that the company earned 58 cents per share, which is lower than the 61 cents per share that analysts estimated. Additionally, its revenue dropped by almost 6% to reach $5.4 billion. This figure is lower than the expected revenue of $6.1 billion.

Freeport CEO Richard Adkerson stated that it was evident how quickly the market sentiment for copper had shifted during this year’s second quarter, with the unexpected decline in the price of copper occurring despite what he saw as resilient demand for the metal. Strong demand is usually seen as a key indicator of economic health.

During the April-to-June quarter this year, the benchmark price of copper dropped by about 20%, which made this the sector’s largest quarterly decline in more than a decade. This in turn sparked worries about the economic health of the industry. On a conference call with investors, Adkerson stated that the current market was tight, noting that there hadn’t been a considerable impact in the physical demand for the red metal.

Before reversing course, the company’s stock had declined by more than 2% on Thursday morning. By midday trading, it had fallen by roughly 0.7%.

Freeport reported its average realized price of copper at $4.03/pound, which is a drop from 2021’s average realized copper price of $4.34/pound. The Phoenix, Arizona-based company noted that it believed its balance sheet was strong enough to overcome the economic storm, adding that it didn’t need to raise any capital.

Adkerson observed that this wasn’t the company’s first rodeo, arguing that Freeport had dealt with similar situations before and had a playbook showing how the situation could be handled. He also noted that the current copper prices weren’t sufficient enough to support new mines, which it expects would worsen the already tight supply of copper globally.

Figures show that in the second quarter of this year, the production of copper increased by more than 17% to reach 1.08 billion pounds.

Freeport-McMoRan Inc. (FCX), closed Thursday's trading session at $29.83, up 1.8436%, on 18,827,064 volume. The average volume for the last 3 months is 18.503M and the stock's 52-week low/high is $24.80/$51.99.

Lordstown Motors Corp. (RIDE)

Green Car Stocks, Schaeffer's, InvestorPlace, The Street, QualityStocks, StocksEarning, MarketBeat, MarketClub Analysis, Trades Of The Day, Daily Trade Alert, CNBC Breaking News, The Online Investor, Early Bird, Kiplinger Today, StreetInsider, BUYINS.NET, The Stock Dork and Cabot Wealth reported earlier on Lordstown Motors Corp. (RIDE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humanity as a whole has come a long way from early men who used rudimentary stone tools. But in our efforts to industrialize, we have caused significant damage to the planet, pumping the atmosphere full of greenhouse gases and converting large swathes of nonagricultural land into agricultural land. Studies have found that cropland expansion is often associated with the exhaustion of critical ecosystem services, loss of biodiversity and higher carbon emissions.

Zero-emission vehicles, which are poised to play a significant role in the fight against climate change, may also be integral in limiting cropland expansion. According to a new paper by Ecological Economics, a faster transition to electric cars in America could cut down expected global cropland expansion by nearly 10% over the next three decades. The paper suggests that rather than cultivating corn to manufacture biofuel for cars in the United States, large parcels of land could be left bare as a means to absorb carbon dioxide.

Researchers believe that using land in this way could result in “substantial” carbon emissions savings on top of the benefits afforded by electrifying America’s road transport system. As it stands, about 25% of the 80,000,000 acres of American land used to produce corn is dedicated to ethanol production. With increasing food prices exacerbating fears of global hunger, campaigners and even some governments have begun calling for an end to the practice of using crops to develop biofuels.

Even though the nation is still a long way from mass electric vehicle adoption, the study indicates that Americans could essentially free up 10% of global corn production by ditching their traditional internal combustion engine (ICE) vehicles for electric cars. A scientist who wasn’t affiliated with the study issued a statement to Carbon Brief saying that the study highlighted an understudied benefit of electrification: it will reduce demand for biofuels and limit the rate of global cropland expansion.

Given that the U.S. produces one-third of global corn supplies, with around 30% of this corn being used to develop ethanol, millions of acres of American land are dedicated to corn production. The resulting cropland expansion has caused significant changes in land use as farmers have cut down forests and grasslands and replaced them with corn farms. This reduces the overall number of plants absorbing carbon dioxide from the atmosphere as corn absorbs a lot less CO2.

The fact that the electric vehicles being developed by various companies such Lordstown Motors Corp. (NASDAQ: RIDE) can have such a beneficial effect on the planet we call home is a great reason why everything possible needs to be done to speed up the uptake of these vehicles.

Lordstown Motors Corp. (RIDE), closed Thursday's trading session at $2.21, up 6.7633%, on 3,386,455 volume. The average volume for the last 3 months is 3.386M and the stock's 52-week low/high is $1.485/$8.93.

The QualityStocks Company Corner

Cub Crafters Inc.

The QualityStocks Daily Newsletter would like to spotlight Cub Crafters Inc.

  • Commercial airlines have seen a resurgence of air travel demand this year following two years of COVID restrictions that kept most people close to home, but many airlines found themselves overwhelmed by the crush of travelers and capped ticket availability
  • Yakima, Washington based CubCrafters Inc. designs, builds, and tests unique light aircraft for those who want to fly themselves
  • The company’s array of aircraft are inspired by the classic Piper PA-18 Super Cub and include a variety of the company’s own Cub-derivative, newly manufactured designs
  • The light and ultralight aircraft market is expected to grow by the end of the decade from annual revenues of $7.5 billion to $11.9 billion at a CAGR of 5.9 percent between 2022 and 2030

When the movie “Top Gun” debuted in 1986, scores of Americans felt inspired to take up flying as a recreational pursuit. With the unveiling of the explosively popular sequel this summer, enthusiasts are seeing a new wave of newcomers to airborne travel ( The ability to crisscross the country in a personal plane is an attainable dream for Americans who love the adventure of seeing life from the air and have the discipline to do the necessary training and budgeting to get off the ground. And after two and a half years of pandemic-related restrictions, summer commercial air travel for recreation surged this year as a result of renewed demand for long-distance vacations. Delta, American, United, JetBlue Airways, Spirit Airlines and Alaska Airlines each capped ticket availability after initially biting off more they could chew this year and having to cancel or delay a large number of flights to accommodate staffing schedules ( Yakima, Wash.-based Cub Crafters (stylized as CubCrafters) has spent decades appealing to those who want to fly themselves by designing, building, testing, and selling best-of-class backcountry airplanes modeled on the classic Piper PA-18 Super Cub light aircraft, and the company’s own Cub-derivative newly manufactured designs.  CubCrafters offers various different models of aircraft that fit under FAA Certified (Part 23), Light Sport Aircraft (“LSA”), and Experimental Amateur Built (E/A-B) classifications.

Cub Crafters Inc. (typically styled CubCrafters) is an OEM aircraft manufacturer based at McAllister Field Airport in Yakima, Washington. The company was founded in 1980 to build parts and supplementary type certificate (STC) improvement modifications, which were used to establish it as the preeminent center for rebuilding the classic Piper PA-18 Super Cub light aircraft. CubCrafters went on to advance the market with its own, newly manufactured aircraft models and holds an approved Federal Aviation Administration (FAA) Production Certificate. Yakima-based operations include an engineering design-test-certification center, aircraft parts and assembly production facilities, and an MRO maintenance service and overhaul facility.

The first newly manufactured aircraft by the company, the CC18-180 Top Cub, was Federal Aviation Administration (FAA) type certified in December 2004. The Top Cub was also granted type certificates (TC) by Transport Canada in July 2008, followed by Australian certification in August of that same year. With the FAA’s release of the new Light Sport Aircraft (LSA) class, CubCrafters created a brand-new model in 2008, the CC11-100 Sport Cub, similarly based on the original Piper J-3 Cub’s appearance, which it validated to ASTM international standards as an LSA. This model advanced to become known as the Carbon Cub, the bestselling LSA of all time in the U.S.

CubCrafters focuses on four main product lines, including the Carbon Cub SS, Carbon Cub FX, XCub, and the Top Cub under license. Some models are built to be lightweight and powerful for quicker flights, while others are built for longer missions in unforgiving backcountry environments.

CubCrafters has a service and overhaul facility for PA-18 Super Cubs and other Cub derivative designs at its Yakima headquarters. The company sells aircraft kits as well as finished aircraft.


The Carbon Cub is available in three variants: Carbon Cub SS (production Light Sport Aircraft), Carbon Cub FX (an innovative Builder Assist E/A-B aircraft) and Carbon Cub EX (E/A-B aircraft kit). Carbon Cub has been designed for off-airport operation with a powerful engine, strong lightweight airframe and nimble low-speed manners. The Carbon Cub has taken the fundamentally superior design of the Piper Super Cub and reinvented it using 21st century materials and computer-aided design. Superior engineering results include the Carbon Cub having 50% fewer parts and weighing more than 300 pounds less than a similarly equipped Super Cub. Now in its third generation of innovation advancements, there are over 1,000 Carbon Cubs flying.

The CubCrafters CC19-180 XCub, FAA Certified and introduced in June 2016, is supplied complete and ready-to-fly. The XCub is a further scaled development of the CubCrafters Carbon Cub, which the company continues to supply, but with higher performance and incorporating more structural carbon fiber. The XCub was developed over a six-year period and not publicly announced until FAA TC had been completed and issued. The process was completed organically using company resources and did not involve any venture capital, loans nor any advanced customer deposits. XCub is built on a wholly original fuselage design. The CNC-milled 4130 chromoly steel frame meets the latest FAA Part 23 certification standards for 2,300-pound gross weight aircraft. XCub’s useful load is as high as 1,084 pounds. Current Part 23 certification requirements ensure this is the strongest Cub ever produced. It can fly farther, providing greater comfort. It is an airplane that has taken the best from the past and, using the very latest in design, material and manufacturing technology, has established a new standard.

The XCub was approved by the FAA for seaplane operations in December 2017. That same month, EASA approved the XCub design and issued a new type certificate. Four international type certificates have been gained: EASA Dec-2017, Canada Feb-2018, Japan April-2018, and Australia Aug-2018.

CubCrafters increased the horsepower of the XCub line in 2019, offering two new models: the CC19-215 FAA Certified version and the CCX-2300 Builder Assist, both powered by the new CC393i 215 HP engine built by Lycoming.

In December 2021, CubCrafters gained FAA Certification of a new nose wheel version of the XCub, branded the NXCub.

Market Overview

According to a 2022 analysis by research firm Expert Market Research (“EMR”), the global ultralight and light aircraft market was valued at $7.63 billion in 2021. The EMR report says the market is expected to grow at a CAGR of 4.5% in the forecast period of 2022-2027 to reach a value of $9.93 billion. Ultralight and light aircraft are small aircraft with on-board pilot (and perhaps passengers) designed for use in recreation, sports, pilot training, aerial surveys, mapping, research and agriculture, humanitarian backcountry access, and special military missions, as well as business and personal travel.

CubCrafters currently enjoys a dominant market share of the rugged adventure airplane market.

Management Team

Patrick Horgan is President and CEO at CubCrafters. Before he assumed that role, he was the company’s Vice President/Director of Engineering & Product Development for three years, when he led the FAA Part 23 type certificate approval and production certificate approval of CubCrafters’ newest flagship, the XCub. Mr. Horgan also directed the breakthrough certification that authorized the use of experimental avionics in FAA-certified production aircraft, a first in aviation history. He brings over 30 years’ aircraft development and manufacturing experience in general aviation, commercial, and military industries. Prior to service at the company, he was the General Manager at WACO Classic Aircraft Corporation in Battle Creek, Michigan, and was the commercial aircraft manager of the Boeing 777 wheel and brake program for Goodrich Aerospace in Troy, Ohio. He was also a designer on the F/A-18 Super Hornet at McDonnell Douglas (now Boeing) in St. Louis, Missouri. Mr. Horgan holds degrees in aeronautical and astronautical engineering from the University of Illinois, and a certificate in Disruptive Strategy from Harvard Business School. He serves as a member of the Board of Directors of the General Aviation Manufacturers Association and on ASTM aircraft standards committees.

Brad Damm is Vice President at CubCrafters. He has overseen CubCrafters’ sales, marketing, and brand management operations since 2018. Since first joining CubCrafters in 2013, Mr. Damm has served as Factory Direct Sales Manager, the Director of Sales Support, the Global Director of Sales, and the Vice President of Sales and Marketing. During his tenure, the company has seen new sales records year after year across all of CubCrafters new aircraft and kit product lines, and the CubCrafters brand has risen to new levels of awareness and respect with aviation consumers worldwide. Prior to joining the company, he served for over 10 years as the Business Development Manager for one of the largest commercial concrete contractors in the Pacific Northwest, driving the sales and revenue growth that allowed the company to expand from a few dozen to hundreds of employees.

Rick Johnson is the Director of Finance at CubCrafters and has been with the company since 2017. He has 27 years of previous experience as controller and CFO for fruit packing and timber operations in the Pacific Northwest. He holds a Bachelor of Science in Business Administration from Central Washington University.

Christopher Matus is Production Manager at CubCrafters and joined the company in 2011. Before taking that post, he held positions as Fabrication Plant Manager, Machine Shop Manager and CNC Machinist for the company. He has also served as a Combat Engineer in the Washington Army National Guard, deploying to Afghanistan and to natural disasters including the 2014 Oso Mudslide.

Justin Jansky is the Administrative Manager at CubCrafters. He joined the company in 2015 and has a demonstrated history of successful collaboration on major FAA type certification projects in the general aviation industry, specifically under 14 CFR Parts 21 and 23. He is responsible for process management, document control, facilitating FAA certification processes, coordination with FAA delegates and documenting compliance testing. He holds a bachelor’s degree in technology and applied design.

Recent News


Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • Canadian province of Ontario recently legalized iGaming, other provinces expected to follow
  • iGaming industry expected to reach 153.6 billion by 2030 at CAGR of 11.7% from 2022 to 2030
  • GMGI offers highly modular, turnkey, and white label gaming solutions for growing B2B customer base
  • Recently released financial results reveal 15 consecutive profitable quarters, 221% Q2-2022 growth

The province of Ontario in Canada has recently joined South Africa, Japan, and many European Union countries in legalizing iGaming ( Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, is positioned to benefit from relaxed legislation that is expected to grow the global iGaming industry.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Thursday's trading session at $4.2, up 1.4493%, on 8,325 volume. The average volume for the last 3 months is 8,325 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

  • Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance
  • Enrollment for Phase 1/2a trial has already started
  • Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment
  • Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin

In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the U.S. Food and Drug Administration (“FDA”) ( to proceed with its planned phase 1/2a first in-human clinical trial and has started enrollment ( The study is designed to evaluate Cybin’s proprietary deuterated psilocybin analog, CYB003. The approval came in the form of a “may proceed” letter and investigational new drug (“IND”) application clearance. Cybin (NEO: CYBN) (NYSE American: CYBN) will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit To view the full press release, visit

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin ( Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Thursday's trading session at $0.568, up 5.1852%, on 803,455 volume. The average volume for the last 3 months is 794,783 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

New research has shown that allowing infants to taste foods that contain wheat, milk, eggs and peanuts as early as the age of three months may decrease an infant’s risk of developing a food allergy. The study, which was led by Professor Karin C. Lødrup Carlsen of the Institute of Clinical Medicine at the University of Oslo, discovered that children who were introduced to these allergenic foods weren’t as likely to develop food allergies by the time they were three years old. For a long time now, the Norwegian Directorate of Health has advised that parents postpone introducing food to their infants in their national recommendations. Figures show that food allergies affect roughly 10% of infants and between 2% to 5% of all children. However, Carlsen argues that this recommendation isn’t valid, noting that researchers had observed an increase in food allergy prevalence throughout the period. Carlsen, who is also a senior pediatrician at the Oslo University Hospital, explained that introducing children to these foods early decreased the prevalence of food allergies in a safe and simple manner. For individuals for whom early exposure to potentially allergenic foods is no longer a preventive option, the treatments being developed by companies such as Aditxt Inc. (NASDAQ: ADTX) can be a viable option because those remedies would reprogram the immune system so that it stops perceiving certain food items as harmful to the body.

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.


AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.


ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.

Aditxt Inc. (NASDAQ: ADTX), closed Thursday's trading session at $0.1558, up 2.1639%, on 1,832,781 volume. The average volume for the last 3 months is 1.833M and the stock's 52-week low/high is $0.1242/$3.95.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is driving the message that fossil fuels do not only damage the climate but also make the world economically vulnerable. This comes amid high fertilizer prices and the inherent presence and effects of climate change, factors threatening the rice production industry worldwide. “Carbon emissions are the leading cause of climate change and global warming issues worldwide. The company’s Hydrogen-Ammonia Synthesizer technology provides the means necessary to store green hydrogen as green ammonia that is completely carbon-free. The hydrogen can be removed when needed for use in fuel cells and other applications based on pure hydrogen technologies,” a recent article needs. “FuelPositive has developed a containerized green ammonia production system relying on renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the two elements in a proprietary converter to form ammonia. The technology will allow farmers to economically produce the amount of ammonia needed to fertilize their crops on-site. In doing so, it eliminates supply chain dependence and stabilizes prices while eliminating carbon emissions. The system can be scaled up or down, so farmers can produce the amount of fertilizer they need right on their farms and apply it when the timing is best.” To view the full article, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.12, up 1.0101%, on 148,417 volume. The average volume for the last 3 months is 148,417 and the stock's 52-week low/high is $0.09/$0.24.

Recent News


The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

  • LQwD is leveraging the Lightning Network for BTC scalability with 19 nodes active and the goal of creating Lightning Network node access in 24 countries by the end of this financial quarter
  • LQwD nodes include US-West, Ireland, India, Germany, Brazil, Hong Kong, Singapore, Sweden, South Korea, South Africa, Bahrain, Indonesia, Italy, Australia, Japan-Osaka, France, Canada, England, and Japan
  • The cryptocurrency market was valued at US $1.6 billion in 2021 and is expected to reach $2.2 billion by 2026, growing at a CAGR of 7.1%

The Federal Reserve Bank of Cleveland Working Paper Series released Working Paper 22-19 in June 2022 entitled “The Lightning Network: Turning Bitcoin into Money.” The FED conjectures early on that the Lightning Network (“LN”) has reduced Bitcoin blockchain congestion and resulted in lower mining fees. Since its introduction in 2009, Bitcoin has grown in value but still has capacity constraints regarding payment processing capability. The average blockchain transaction only allows seven transactions per second, which pales in comparison with centralized payment infrastructures like Visa or Mastercard (

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.


The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Thursday's trading session at $0.0949, up 20.1266%, on 500 volume. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $0.0637/$0.672.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Millions of Americans who grew up during the prohibition era were taught that cannabis is an inherently dangerous drug that encourages drug abuse and criminal activity. To them, cannabis was as dangerous as narcotics such as heroin or cocaine, perhaps even more dangerous because a large focus of the failed war on drugs was on cannabis. The millennial generation, however, generally holds a different view on cannabis compared to older generations. Nearly 20 states have now passed adult-use cannabis legislation, and in most of these regions, millennials played a significant role in enacting cannabis reform. Sometimes referred to as generation Y, this generation essentially pioneered recreational cannabis reform, at least in the United States, thanks to its ability to be open to new experiences. While older generations can be closed minded, especially regarding controversial issues such as cannabis, millennials are more open minded, putting them at the forefront of social development and change. Savvy companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will likely study these survey findings and glean any insights that could help in shaping their future marketing and product development efforts.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Thursday's trading session at $0.012, up 5.2632%, on 826,776 volume. The average volume for the last 3 months is 585,277 and the stock's 52-week low/high is $0.0102/$0.073.

Recent News

American Cannabis Partners

The QualityStocks Daily Newsletter would like to spotlight American Cannabis Partners.

American Cannabis Partners (ACP) is a multi-state cannabis company with 560,000 square feet of licensed canopy space for cultivation and one retail license. The company is nationally headquartered in Trinity County of Northern California’s Emerald Triangle.

ACP is focused on three complementary business segments: real estate, acquisition & development of proprietary assets, and ongoing cultivation operations. Led by a seasoned management team with 30+ years of canna-business experience, ACP’s strategy is to capture opportunities in real estate and licensing in states that have recently passed cannabis legalization legislation, thereby equipping the company to capitalize on Federal interstate commerce opportunities.

Through its current cultivation operations, ACP supplies approximately 80% of its whole flower products for manufacturing, distribution and retail licenses. With the remaining 20%, the company supplies its proprietary strains to select California distributors and its own Michigan retail location under its exclusive in-house brand, ZÜK.

History of American Cannabis Partners

In 2014, Stephen Jordan, President of ACP, took on the Director of Operations position for a U.S.-based company operating in the Jamaican cannabis space. Over the course of his three-year tenure in this role, Jordan developed a number of relationships that would help serve as the basis of American Cannabis Partners.

One such relationship was with Junior Gordon, a cultivation lead grower from Jamaica’s Westmoreland Parish. Jordan immediately saw the value of Gordon’s unique skillset and credentials, and Gordon recognized Jordan’s heartfelt vision of bringing Jamaican culture to the rapidly developing U.S. cannabis space.

Guided by that mission, ACP’s unchanging goal is to improve the lives of individuals through cannabis and business.

Current Operations

Since its founding in 2018, privately-owned American Cannabis Partners has established a foothold in two key U.S. cannabis markets – California and Michigan. In total, the company has acquired 12 cannabis licenses, including 20,000 sq. ft. of cultivation licenses in California and 540,000 sq. ft. of cultivation licenses & one retail license in Michigan.

ACP’s IP portfolio features three proprietary strains sold exclusively through the company’s wholly owned ZÜK brand, as well as proprietary data collection and mining systems supporting its cultivation and retail operations.

Plans for Expansion

American Cannabis Partners is pursuing additional growth in the cannabis sector through multiple planned initiatives. These include:

  • Submitting applications for additional cultivation licenses at the company’s Trinity County, California, location;
  • Planning land acquisition and project development strategies for expanding operations to its third U.S. state beginning in the second quarter of 2022; and
  • Planning land acquisition and project development strategies for expanding operations to its fourth U.S. state beginning in the second quarter of 2024.

ACP is currently exploring expansion opportunities through partnerships and joint ventures in New Jersey, New York, Virginia, Nevada, Arizona, Missouri and Massachusetts.

Management Team

Stephen Jordan is the CEO of American Cannabis Partners. He is focused on the first and last steps of legal cannabis – cultivation and retail. To date, Mr. Jordan has provided the company with ownership of 12 licenses, three proprietary cannabis strains and multiple real estate assets. His background in cannabis operations and financial strategies has guided American Cannabis Partners’ efforts to produce consistently high-quality product for both the medical and recreational segments. Mr. Jordan has operated under cultivation, manufacturing, distribution, medical research (Univ. of West Indies), retail and exportation licenses in multiple countries, further strengthening his network within the cannabis industry.

Gary Coltek is the company’s Chief Operating Officer. He has credentials based in the culinary, hospitality and sustainability industries spanning over 40 years, including taking three companies public. Mr. Coltek has held management positions internationally with Ritz Carlton, Four Seasons, Trump Hospitality, Phymatrix and International Oncology Network. For 17 years, he was the founding member and partner of a private boutique consulting firm. He is currently a guest speaker and visiting professor at universities in Israel, China, Italy, the Netherlands and Peru, covering topics that include culinary sustainability, sustainable cannabis farming, organic sustainable farming and cannabis clinical studies.

Scot C. Crow is the Lead Corporate Counsel for American Cannabis Partners. He has extensive experience in corporate mergers & acquisitions and tax law. His clients rely on him to advise them with respect to their complex financial transactions and provide outside general counsel. Mr. Crow provides his clients proactive advice with respect to sensitive management matters, litigation management, day to day transactional needs and objective assessments for the development of successful business strategies. His experience includes serving as lead counsel for numerous mergers & acquisitions, private equity investments, private offerings, venture capital financings, mezzanine debt offerings, divestures and other related transactions, with an emphasis in the legalized marijuana segment.

Jacob Frenkel is the company’s Lead Compliance Counsel. He is the current Chair of Dickinson Wright’s Government Investigations and Securities Enforcement Practice. Mr. Frenkel’s solutions-minded approach to issues has earned him a reputation as an aggressive, tenacious, creative and proactive defense lawyer and litigator. After 14 years as a Senior Counsel in the SEC’s Division of Enforcement, U.S. federal criminal prosecutor and New Orleans Assistant District Attorney, Mr. Frenkel has practiced in the private sector for 20 years. His unique mix of corporate transactional, litigation and investigations defense clients extend well beyond the cannabis industry and cover a wide range of industries worldwide.

Junior Gordon is the Director of Cultivation for American Cannabis Partners. With 30 years of international cannabis cultivation experience in both the Caribbean and United States, Mr. Gordon is recognized as one of the top growers in the world. His skills span both controlled indoor and large volume outdoor harvest programs, giving him proficiency in nursery, propagation and indoor & outdoor grow strategies. As a winner of High Times and other notable Cannabis Cups, his focus is on connecting the dots between propagation, soil, irrigation, planting, harvesting, curing, processing and inventory control, bringing Jamaican cannabis cultivation best practices to American Cannabis Partners’ operations.

Recent News


QSAM Biosciences Inc. (OTCQB: QSAM)

The QualityStocks Daily Newsletter would like to spotlight QSAM Biosciences Inc. (OTCQB: QSAM).

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R),” a recent article reads. “This is an important milestone for QSAM,” said the company’s co-founder and CEO Douglas R. Baum. “Successfully treating patients with primary or secondary bone cancer remains an area of significant unmet medical need and a goal for CycloSam(R).” To view the full article, visit

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.


CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

  • Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
  • Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
  • Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Market Outlook

Through its ongoing development of CycloSam®, QSAM Biosciences is targeting multiple large and underserved market opportunities. According to the American Cancer Society, roughly 400,000 new cases of malignant bone metastasis are diagnosed annually in the U.S. alone. Additionally, QSAM will pursue indications for osteosarcoma and Ewing’s sarcoma that are the most common primary malignancies of bone tissues in children.

Despite this pressing need, the current standard of care for bone cancer is aggressive and suboptimal, leading to marginal success with significant side effects and poor long-term survival prognosis. As a result, QSAM Biosciences estimates a sizable market opportunity for its development pipeline.

  • Bone Metastasis has an estimated total addressable market of $20 billion in the U.S. based on total new cases and comparable drug pricing.
  • Osteosarcoma/Ewing’s Sarcoma have a total addressable market of roughly $125 million in the U.S. based on approximately 1,000 new cases in 2021.
  • The total addressable market for Bone Marrow Ablation is projected at $1 billion, with an estimated 32,000 procedures completed annually.

The company anticipates that the ability to administer CycloSam® for higher and multiple-dose regimens may expand its clinical utility for therapeutic uses in additional areas of high unmet medical needs.

Management Team

QSAM Biosciences is led by an experienced management team and board with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

Dr. C. Richard Piazza is the Executive Chairman of QSAM Biosciences. Since 2017, he has also served as President and CEO of IGL Pharma Inc., the licensor of CycloSam®, and as a consultant to IsoTherapeutics Group LLC, the inventors of the technology. Dr. Piazza also currently serves on the board of directors of NovaScan LLC, a privately held cancer detection and diagnostics company. He has more than 48 years of health care experience in both medical devices and pharmaceutical/biotech and has led several technology companies to market success, including numerous FDA approvals in both sectors. Dr. Piazza obtained a BS in Economics and a BS in Speech Pathology from the State University of New York and an MA & PhD in Economics from the University of Buffalo and Leeds University.

Douglas R. Baum is the company’s CEO and Director. He brings to QSAM Biosciences over 30 years of experience in the bioscience and biotech industries, including development, FDA/EMA approval and commercialization of multiple drugs and medical devices. Mr. Baum has overseen 15 product approvals through the FDA and EMA and raised over $85 million in capital to fund breakthrough technologies. From 2017 to 2020, he consulted with multiple medical schools and biotech and pharmaceutical companies, and, from 2012 to 2017, he served as President, Chief Executive Officer and Director of Xeris Pharmaceuticals Inc. Mr. Baum holds a Master of Science in Technology Commercialization and a BBA in International Business and Marketing from the University of Texas.

Adam King is the CFO of QSAM Biosciences. He is also the Founder and CEO of King Consulting Group, where he provides a range of financial and reporting services for clients. Before founding King Consulting Group in January 2021, Mr. King was the CFO for Netsertive, a venture-backed digital marketing company. From 2016 to 2018, he was the Office Managing Audit Director for BDO’s Greenville, South Carolina, office, in addition to serving as Audit Director in Raleigh, North Carolina, and Boston, Massachusetts. While at BDO, Mr. King worked with various clients, from tech and life science start-ups to billion-dollar publicly traded companies. He holds a Bachelor of Science in Accounting from Elon University and is a CPA in Raleigh, North Carolina.

QSAM Biosciences Inc. (OTCQB: QSAM), closed Thursday's trading session at $5.0787, even for the day, on 25 volume. The average volume for the last 3 months is 25 and the stock's 52-week low/high is $3.50/$20.40.

Recent News

DPCM Capital Inc. (NYSE: XPOA)

The QualityStocks Daily Newsletter would like to spotlight DPCM Capital Inc. (NYSE: XPOA).

  • DPCM Capital stockholders have been offered an innovative bonus pool structure that incentivizes stockholders and reduces their cost basis per share by as much as 31%
  • The bonus pool is highlighted ahead of the July 29, 2022 redemption deadline to incentivize ongoing retention and long-term investment in D-Wave by DPCM Capital stockholders

DPCM Capital (NYSE: XPOA), a special purpose acquisition company, and D-Wave Systems Inc., a leader in quantum computing systems, software, and services, have highlighted an innovative bonus pool structure for DCPM Capital stockholders in advance of the deadline for redemption at 5:00 p.m. EDT on July 29, 2022. Upon closing of the proposed business combination between DPCM Capital and D-Wave, a new company, D-Wave Quantum Inc., will become the parent company of D-Wave Systems and DPCM, and is expected to trade on the NYSE under the ticker symbol ‘QBTS’ (

DPCM Capital Inc. (NYSE: XPOA), a special purpose acquisition company, on February 9, 2022, announced its entry into a definitive transaction agreement with D-Wave Systems Inc., a company with approximately 20 years of experience in pioneering superconducting annealing quantum computers. Upon closing of the transaction, shares of D-Wave Quantum Inc. – a newly formed company that will be the parent company of D-Wave Systems and DPCM Capital – are expected to trade on the NYSE under ticker symbol ‘QBTS’.

The transaction, which is subject to the satisfaction of customary closing conditions, is expected to enhance D-Wave’s leadership in commercial quantum computing and accelerate quantum use cases into significant customer segments.

D-Wave is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

DPCM Capital Inc. (NYSE: XPOA), closed Thursday's trading session at $8.72, off by 12.6253%, on 986,494 volume. The average volume for the last 3 months is 983,675 and the stock's 52-week low/high is $8.68/$10.33.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

  • CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players
  • Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries
  • Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury
  • Retired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board for Odyssey Health to help guide and promote public information regarding Odyssey’s treatment developments
  • Wambach recently appeared on the Stock2Me podcast to discuss her interest in concussion research and her role on Odyssey’s sports board

The Center for Disease Control estimates that 5 to 10 percent of athletes will experience a concussion in any given sports season, marking the brain injury events as very common among athletes. Soccer and football stand out as that may exact a heavy toll in traumatic brain injuries (“TBIs”) because of the way head and neck impacts form a part of the games. The University of Michigan’s Health department cites statistics on the web page for its multidisciplinary NeuroSport program showing about 3.8 million concussions occur each year in the United States from sports-related injuries ( Retired pro soccer forward Abby Wambach and retired pro football quarterbacks Kurt Warner and Brett Favre have expressed hopes that medical science will yet be able to gain a better understanding of TBIs and how to treat them, particularly in regard to sports athletes. The trio have expressed a willingness to let forensic researchers learn from their donated cadaver brains to advance medical science, and they have formed a Sports Advisory Board for Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY), a company that is preparing for human trials of a drug product-device combination it believes will ultimately help concussion-injured individuals to quickly heal and recover.  Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild traumatic injury within the first few minutes after an incident is advancing in a phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview,” a recent article reads. “No U.S. Food and Drug Administration (‘FDA’)-approved drug exists at this point, creating a particular opportunity for the company. The other drug substance is a novel compound intended to treat neurodegenerative Niemann-Pick disease, which leaves patients with an average lifespan of five to 20 years beyond diagnosis.” To view the full article, visit

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Thursday's trading session at $0.1775, off by 6.5789%, on 134,655 volume. The average volume for the last 3 months is 134,655 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

The United States Drug Enforcement Administration (DEA) has been sued again for refusing to permit a doctor to treat patients with terminal illnesses using psilocybin therapy in accordance with state and federal Right To Try laws. Numerous trials have found that psilocybin, as well as MDMA, possess the potential to treat a range of mental health conditions, with the United States Food and Drug Administration (FDA) designating them as breakthrough therapies. Right To Try laws are aimed at increasing access to Schedule I investigational therapies that haven’t received approval for general use. The DEA is also facing political pressure from bipartisan legislators filing measures in the Senate and House to reassert that the Right To Try laws should include psychedelic drugs. As the wall of psychedelic prohibition is chipped away one bit at a time, industry companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) could one day operate within a regulatory landscape that is more enabling than it is currently.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Thursday's trading session at $0.039, off by 10.7551%, on 6,341 volume. The average volume for the last 3 months is 6,341 and the stock's 52-week low/high is $0.03/$0.315.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.